Abstracts Archive - Page 384 of 2607 - ACR Meeting Abstracts

Abstract Number: 1314 • ACR Convergence 2023
Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA
Nora Singer¹, Maya Breitman², Maricela Haghiac², Larraine Gordesky³, Jane Reese⁴, Steven Lewis², Emma Barnboym², Noor Hussein⁵, Susan Lasalvia⁶, Elizabeth Mellins⁷, Tracey Bonfield⁸, Donald Anthony⁹, Arnold Caplan¹⁰ and Hillard Lazarus⁸, ¹The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ²The MetroHealth System at CWRU, Cleveland, OH, ³The MetroHealth System at CWRU and Louis Stokes Cleveland VA, Cleveland, OH, ⁴CWRU, University Hospitals of Cleveland, Cleveland, OH, ⁵Stanford University, Palo Alta, CA, ⁶The MetroHealth System, Cleveland, OH, ⁷Stanford University, Stanford, CA, ⁸CWRU and University Hospitals of Cleveland, Cleveland, OH, ⁹Case Western Reserve University, Cleveland VA Medical Center, The MetroHealth System, Cleveland, OH, ¹⁰CWRU, Center for Skeletal Biology, Cleveland, OH
Background/Purpose: The purpose of this study was to evaluate the safety of bone-marrow derived allogeneic mesenchymal stem cells (MSCs) as therapeutic agents in early rheumatoid…
Abstract Number: 1282 • ACR Convergence 2023
Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
Meliha Kapetanovic¹, Olivia Olsson², Jon Einarsson¹, Morteza Najibi³ and Ellen Tufvesson⁴, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Lund University, Faculty of Medicine, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund, Lund, Sweden, ⁴Lund University, Institution for clinical scienses, section for lung medicine and allergy, Lund, Sweden
Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…
Abstract Number: 1304 • ACR Convergence 2023
Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy
Vivian Bykerk¹, Isabel Castrejon², Vibeke Strand³, Stephanie Dahan⁴, Raul Castellanos-Moreira⁵, Leo Chen⁶ and Wayne Little⁴, ¹Department of Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³Stanford University, Palo Alto, CA, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Madrid, Spain, ⁶Syneos Health, Vancouver, BC, Canada
Background/Purpose: RA is a chronic disease that can lead to irreversible damage and functional decline with delayed or inadequate treatment.1 Abatacept + MTX is effective…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1329 • ACR Convergence 2023
R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Yan Chen¹, Sothy Yi¹, Vadim Markovtsov¹, Bhushan Samant¹, Andrew Chow¹, Esteban Masuda¹ and Simon Shaw², ¹Rigel Pharmaceuticals, Inc, South San Francisco, CA, ²Rigel Pharmaceuticals, Inc., South San Francisco, CA
Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
Abstract Number: 1307 • ACR Convergence 2023
Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER
Clementina López Medina¹, Jerusalem Calvo², Lucia Otero-Valera³, Alejandro Escudero Contreras², Rafaela Ortega Castro⁴, Lourdes Ladehesa Pineda⁵, Cristina Campos⁶, Pilar Bernabeu-Gonzálvez⁷, Cristina Bohorquez⁸, Alicia Garcia Dorta⁹, Dolores Ruiz-Montesinos¹⁰, Manuel Enrique Pombo Suarez¹¹, Inmaculada Ros¹², Fernando Alonso³ and Isabel Castrejon¹³, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ⁶Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁷General University Hospital Dr. Balmis, Alicante, Spain, ⁸Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ⁹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities, compared to the general population. The presence of such comorbidities has been directly…
Abstract Number: 1330 • ACR Convergence 2023
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial
John Lampa¹, Dan Nordstrom², Ronald van Vollenhoven³, Merete Hetland⁴, Espen A Haavardsholm⁵, Mikkel Østergaard⁶, Anna Rudin⁷, Marte Schrumpf Heiberg⁵, Michael Nurmohamed³, Bjorn Gudbjornsson⁸, Kristina Lend⁹, Kim Hørslev-Petersen¹⁰, Tuulikki Sokka-Isler¹¹, Gerdur Maria Grondal¹², Simon Krabbe¹³, Joakim Lindqvist¹⁴, Anna-Karin Hultgård Ekwall¹⁵, Daniel Glinatsi¹⁶, Meliha Kapetanovic¹⁷, Cidem Gentline¹⁴, Anna-Birgitte Aga¹⁸, Heikki Relas², Tove Lorenzen¹⁹, Giovanni Cagnotto²⁰, Johan Back²¹, Oliver Hendricks²², Bas Dijkshoorn²³, Kajsa Öberg²⁴, Maud-Kristine Aga Ljoså²⁵, Eli Brodin²⁶, Hanne Merete Lindegaard²⁷, Annika Söderbergh²⁸, Milad Rizk²⁹, Alf Kastbom³⁰, Per Larsson³¹, Line Uhrenholt³², Søren Just³³, David J Stevens³⁴, Trine B Laurberg³⁵, Gunnstein Bakland³⁶, Inge Olsen³⁷, Joseph Sexton¹⁸ and Till Uhlig¹⁸, ¹Stockholm County, Hãsselby, Sweden, ²Helsinki University Hospital, Helsinki, Finland, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁸Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹⁰University of Southern Denmark, Odense, Denmark, ¹¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹³Herlev-Gentofte University Hospital, Herlev, Denmark, ¹⁴Karolinska University Hospital, Stockholm, Sweden, ¹⁵Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ¹⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ¹⁷Lund University and Skåne University Hospital, Lund, Sweden, ¹⁸Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Silkeborg University Hospital, Silkeborg, Denmark, ²⁰Skåne University Hospital, Lund, Sweden, ²¹Uppsala University Hospital, Uppsala, Sweden, ²²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²³Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, ²⁴Falu Hospital, Falun, Sweden, ²⁵Ålesund Hospital, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Odense Hospital, Odense, Denmark, ²⁸Örebro University Hospital, Örebro, Sweden, ²⁹Västmanlands Hospital Västerås, Västerås, Sweden, ³⁰Linköping University, Linköping, Sweden, ³¹Academic Specialist Center, Stockholm, Sweden, ³²Aalborg University Hospital, Aalborg, Denmark, ³³Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, ³⁴St. Olavs Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…
Abstract Number: 1318 • ACR Convergence 2023
Abatacept Modulates Both Global and Citrulline Specific T Cell Signatures: Results from Inhibition of Co-Simulation in Rheumatoid Arthritis Phase IV Trial
Ravi Kumar Sharma¹, Aysin Tulunay Virlan², Louise Bennett³, John Cole³, Sam McAllister², Sara Turcinov⁴, Samantha Miller³, Fraser Morton³, Ashley Gilmour³, Sean Kerrigan³, Anatoly Dubnovitsky¹, Leonid Padyukov⁵, Caron Paterson³, William Kwok⁶, René Toes⁷, Lars Klareskog⁸, Arthur Pratt⁹, John Isaacs¹⁰, Sean Connolly¹¹, Duncan Porter³, Stefan Siebert¹², Iain McInnes³, Vivianne Malmström⁸ and Carl Goodyear³, ¹Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Solna, Sweden, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Immunity and Inflammation Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, ¹⁰Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle Hospitals, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²School of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Clinical outcomes in Rheumatoid arthritis (RA) have improved with the introduction of biological and targeted synthetic disease modifying anti-rheumatic drugs (b & tsDMARDs). Abatacept…
Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
Abstract Number: 1211 • ACR Convergence 2023
Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population
Rachel Dayno¹, Michael George¹, Kimberly DeQuattro², Marissa Blum³, Sharon Kolasinski⁴ and Dana DiRenzo⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania, Cherry Hill, NJ, ⁴University of Pennsylvania, Philadephia, PA, ⁵University of Pennsylvania, Bala Cynwyd, PA
Background/Purpose: Self-efficacy (SE) is the inner belief in one's ability to succeed in specific situations and tasks. SE for managing the symptoms and emotions associated…
Abstract Number: 1306 • ACR Convergence 2023
Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapaa-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹¹, Virginia Pascual Ramos¹², Irazú Contreras Yañez¹³, Iris Colunga¹⁴, Dionicio A. Galarza-Delgado¹⁴, José Ramón Azpiri-López¹⁴, Silvia Rolefstad¹⁵, Anne Grete Semb¹⁶, Durga P Misra¹⁷, George Kitas¹⁸ and Ellen-Margrethe Hauge¹⁹, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Umeå University, Umeå, Umea, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Manitoba, MB, Canada, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁴Hospital Universitario UANL, Monterrey, Mexico, ¹⁵Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ¹⁹Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Baseline and cumulative inflammation have both been associated with increased cardiovascular event (CVE) risk in patients with rheumatoid arthritis (RA). Statin therapy reduced systemic…
Abstract Number: 1272 • ACR Convergence 2023
Immunomodulators and Risk for Breakthrough COVID-19 After a Third SARS-CoV-2 mRNA Vaccine Among Patients with Rheumatoid Arthritis: A Cohort Study
Abigail Schiff¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Jennifer Hanberg³, Emily Kowalski¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade⁴, Alene Saavedra¹, Shruthi Srivatsan², Zachary Williams², Rathnam Venkat¹, Zachary Wallace⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In August 2021, the CDC recommended a third SARS-CoV-2 mRNA vaccine dose to complete the initial vaccine series for immunosuppressed patients who had previously…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1229 • ACR Convergence 2023
Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus
Tala El Tal¹, justine ledochowski², Sarah Mossad³, Victoria Lishak³, Ibrahim Mohamed⁴, Joanna Law³, Lawrence Ng³, Paris Moaf³, Asha Jeyanathan³, Adrienne Davis³, Linda Hiraki³, Deborah Levy³, Zahi Touma⁵, Natoshia Cunningham⁶, Ashley Danguecan³ and Andrea Knight³, ¹Division of Rheumatology, The Hospital for Sick Children, andDivision of Rheumatology, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada, ²Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Brampton, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Michigan State University, Grand Rapids, MI
Background/Purpose: Cognitive dysfunction (including executive dysfunction) affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), with potential adverse effects on health-related quality…
Abstract Number: 1090 • ACR Convergence 2023
Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Shelby Gomez¹, Trisha Ludwig¹, Katherine Hartkopf², Sancia Ferguson³, Lori Zemlicka⁴, Mindy Jones⁵ and Christie M. Bartels⁶, ¹UW Health Pharmacy, Madison, WI, ²Pharmacy Society of Wisconsin, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴UW Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].